# PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function

> **NCT00328692** · PHASE3 · COMPLETED · sponsor: **NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 932 (actual)

## Conditions studied

- Heart Failure, Congestive

## Interventions

- **DRUG:** rolofylline
- **DRUG:** Comparator: Placebo (unspecified)

## Key facts

- **NCT ID:** NCT00328692
- **Lead sponsor:** NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 932 (ACTUAL)
- **Last updated:** 2009-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00328692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00328692, "PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00328692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*